{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:05:19Z","timestamp":1789754719368,"version":"4.0.1"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    <jats:bold>Background<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>Tuberculosis (TB) remains an important public health problem in Ghana, while rifampicin-resistant TB (RR-TB) poses an additional challenge to TB control. Routine molecular diagnostic data can provide useful information on temporal patterns of TB detection and drug resistance, particularly in regions where population-based surveillance data are limited. However, findings from referral facilities may be influenced by referral patterns and access to diagnostic services and should therefore be interpreted within their health-system context.<\/jats:p>\n                  <jats:p>We conducted a cross-sectional study using historical GeneXpert MTB\/RIF data collected from January 2019 to December 2024 at the Upper East Regional Hospital (UERH), a regional referral facility in Bolgatanga, Ghana. Data were extracted from GeneXpert laboratory and TB programme registers for patients tested for presumptive TB. MTB detection and rifampicin resistance were determined from GeneXpert MTB\/RIF results. Temporal differences in categorical outcomes were assessed using Pearson\u2019s chi-square test of independence. Multivariable logistic regression was used to identify factors independently associated with rifampicin resistance.<\/jats:p>\n                  <jats:p>A total of 6,897 GeneXpert MTB\/RIF tests were included. The mean age of the tested population was 44.6\u2009\u00b1\u200920.4 years, and 56.7% were male. MTB was detected in 1,083 tests (15.7%). MTB detection varied significantly across study years (\u03c7\u00b2\u2009=\u200928.46, p\u2009&lt;\u20090.001), with positivity ranging from 9.8% in 2022 to 20.9% in 2021. Among MTB-positive tests, 192\/1,083 (17.7%) showed rifampicin resistance. The annual proportion of rifampicin resistance ranged from 9.5% in 2020 to 23.1% in 2023 and varied significantly across years (\u03c7\u00b2\u2009=\u200927.13, p\u2009&lt;\u20090.001). Low MTB bacterial load was significantly more frequent among rifampicin-resistant cases. In multivariable analysis, female sex was associated with higher odds of rifampicin resistance after adjustment for age and MTB bacterial-load category (aOR = 1.44, 95% CI: 1.02\u20132.02; p\u2009=\u20090.037), while low MTB bacterial load was independently associated with rifampicin resistance after adjustment for age and sex (aOR = 9.62, 95% CI: 5.77\u201316.04; p\u2009&lt;\u20090.001).<\/jats:p>\n                  <jats:p>MTB detection and rifampicin resistance showed substantial year-to-year variation among patients tested at UERH during 2019\u20132024. The 17.7% rifampicin-resistance proportion represents a hospital-based estimate among MTB-positive GeneXpert-tested cases and should not be interpreted as the population prevalence of RR-TB in the Upper East Region. The observed pattern nevertheless warrants further investigation to determine the contribution of referral patterns, targeted testing, previous treatment, and other programme factors to the high proportion of rifampicin resistance observed at this referral facility.<\/jats:p>","DOI":"10.1371\/journal.pone.0346447","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:21:37Z","timestamp":1789752097000},"page":"e0346447","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Annual trends in Mycobacterium tuberculosis detection and rifampicin resistance at a regional referral hospital in Northern Ghana, 2019\u20132024"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3121-6114","authenticated-orcid":true,"given":"Solomon","family":"Wireko","sequence":"first","affiliation":[{"name":"Kumasi Technical University","place":["Kumasi, Ghana"],"department":["Department of Laboratory Technology, Faculty of Health Science"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Nyarko","sequence":"additional","affiliation":[{"name":"Medicare College of Applied Sciences","place":["Kumasi, Ghana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine Harley","family":"Arthur-Quayson","sequence":"additional","affiliation":[{"name":"Medicare College of Applied Sciences","place":["Kumasi, Ghana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"Abu","sequence":"additional","affiliation":[{"name":"Upper East Regional Hospital","place":["Bolgatanga, Ghana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Appiah","sequence":"additional","affiliation":[{"name":"Upper East Regional Hospital","place":["Bolgatanga, Ghana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Ofosu","sequence":"additional","affiliation":[{"name":"Kumasi Technical University","place":["Kumasi, Ghana"],"department":["Department of Laboratory Technology, Faculty of Health Science"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kwarteng","sequence":"additional","affiliation":[{"name":"College of Science, Kwame Nkrumah University of Science and Technology","place":["Kumasi, Ghana"],"department":["Department of Biochemistry and Biotechnology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Gameli","family":"Deku","sequence":"additional","affiliation":[{"name":"School of Allied Health Sciences, University of Health and Allied Sciences","place":["Ho, Ghana"],"department":["Department of Medical Laboratory Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebenezer","family":"Senu","sequence":"additional","affiliation":[{"name":"Elite Research and Data Science Institute","place":["Kumasi, Ghana"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"pone.0346447.ref001","volume-title":"Global tuberculosis report 2024","author":"World Health Organization","year":"2024"},{"issue":"4","key":"pone.0346447.ref002","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S2213-2600(18)30057-2","article-title":"The global tuberculosis epidemic and progress in care, prevention, and research","volume":"7","author":"K Floyd","year":"2019","journal-title":"Lancet Respir Med"},{"key":"pone.0346447.ref003","doi-asserted-by":"crossref","first-page":"16076","DOI":"10.1038\/nrdp.2016.76","article-title":"Tuberculosis","volume":"2","author":"M Pai","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"pone.0346447.ref004","volume-title":"WHO operational handbook on tuberculosis: Module 4\u2014Treatment of drug-resistant tuberculosis","author":"World Health Organization","year":"2022"},{"key":"pone.0346447.ref005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2021.02.107","article-title":"Global tuberculosis report 2020\u2014reflections on the global TB burden, treatment and prevention efforts","volume":"113","author":"J Chakaya","year":"2021","journal-title":"Int J Infect Dis"},{"key":"pone.0346447.ref006","article-title":"The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis","author":"K Dheda","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"11","key":"pone.0346447.ref007","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa0907847","article-title":"Rapid molecular detection of tuberculosis and rifampin resistance","volume":"363","author":"CC Boehme","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0346447.ref008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193577","article-title":"Multidisease testing for HIV and TB using the GeneXpert platform: A feasibility study in rural Zimbabwe","volume":"13","author":"Z Ndlovu","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"pone.0346447.ref009","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009593.pub2","article-title":"Xpert\u00ae MTB\/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults","author":"KR Steingart","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0346447.ref010","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eclinm.2019.06.015","article-title":"Geographical Accessibility to District Hospitals\/Medical Laboratories for Comprehensive Antenatal Point-of-Care Diagnostic Services in the Upper East Region, Ghana","volume":"13","author":"D Kuupiel","year":"2019","journal-title":"EClinicalMedicine"},{"issue":"6","key":"pone.0346447.ref011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198695","article-title":"Evaluation of the GeneXpert MTB\/RIF in patients with presumptive tuberculous meningitis","volume":"13","author":"T Metcalf","year":"2018","journal-title":"PLoS One"},{"issue":"2","key":"pone.0346447.ref012","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4103\/ijmy.ijmy_83_19","article-title":"Evaluation of GeneXpert Mycobacterium tuberculosis\/Rifampin for the detection of Mycobacterium tuberculosis complex and rifampicin resistance in nonrespiratory clinical specimens","volume":"8","author":"M Habous","year":"2019","journal-title":"Int J Mycobacteriol"},{"issue":"7","key":"pone.0346447.ref013","first-page":"1441","article-title":"Drug resistance in Ghana","volume":"17","author":"D Yeboah-Manu","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"pone.0346447.ref014","volume-title":"National TB Control Programme Annual Report","author":"Ghana Health Service","year":"2022"},{"issue":"6","key":"pone.0346447.ref015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252819","article-title":"The burden of drug resistance tuberculosis in Ghana; results of the First National Survey","volume":"16","author":"AA Sylverken","year":"2021","journal-title":"PLoS One"},{"issue":"6","key":"pone.0346447.ref016","article-title":"Trends of Mycobacterium tuberculosis and rifampicin resistance at the Ho Teaching Hospital in Ghana","volume":"19","author":"JG Deku","year":"2024","journal-title":"PLoS One"},{"key":"pone.0346447.ref017","first-page":"455","article-title":"Trends in TB case detection in Ghana","volume":"16","author":"E Osei","year":"2016","journal-title":"BMC Public Health"},{"issue":"1","key":"pone.0346447.ref018","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/pathogens13010027","article-title":"Rapid Diagnosis of Drug-Resistant Tuberculosis-Opportunities and Challenges","volume":"13","author":"K Naidoo","year":"2023","journal-title":"Pathogens"},{"issue":"5980","key":"pone.0346447.ref019","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1185449","article-title":"The population dynamics of tuberculosis","volume":"328","author":"C Dye","year":"2010","journal-title":"Science"},{"issue":"6","key":"pone.0346447.ref020","doi-asserted-by":"crossref","first-page":"436","DOI":"10.5588\/ijtld.21.0148","article-title":"The impact of COVID-19 on TB: a review of the data","volume":"25","author":"CF McQuaid","year":"2021","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"pone.0346447.ref021","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1164\/rccm.200503-449OC","article-title":"Reinfection and mixed infection cause changing Mycobacterium tuberculosis drug-resistance patterns","volume":"172","author":"A van Rie","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"pone.0346447.ref022","article-title":"Tuberculosis 2015: burden, challenges and strategy","volume":"16","author":"M Raviglione","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"9785","key":"pone.0346447.ref023","first-page":"57","article-title":"Tuberculosis control in Africa","volume":"378","author":"SD Lawn","year":"2011","journal-title":"Lancet"},{"key":"pone.0346447.ref024","doi-asserted-by":"crossref","first-page":"1027394","DOI":"10.3389\/fcimb.2022.1027394","article-title":"The evolving biology of Mycobacterium tuberculosis drug resistance","volume":"12","author":"RM Jones","year":"2022","journal-title":"Front Cell Infect Microbiol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0346447","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:21:45Z","timestamp":1789752105000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0346447"}},"subtitle":[],"editor":[{"given":"Padmapriya P","family":"Banada","sequence":"first","affiliation":[{"name":"Rutgers Biomedical and Health Sciences","place":["UNITED STATES OF AMERICA"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0346447","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]}}}